Loading cancer entity…
Loading cancer entity…
Clinical trials
359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | terminated | Phase 3 | 107 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | terminated | Phase 3 | 1,272 | BayerINDUSTRY | 13 | Jul 28, 2025 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | terminated | Phase 3 | 93 | BayerINDUSTRY | 9 | May 3, 2023 | clinicaltrials |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | terminated | Phase 3 | 103 | BayerINDUSTRY | 5 | Jun 30, 2022 | clinicaltrials |
| NCT02425878 | Ulipristal Acetate 10 mg and Asisted Reproduction | terminated | Phase 3 | 2 | Instituto Valenciano de Infertilidad, IVI VALENCIAOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | terminated | Phase 3 | 38 | Gynecologic Oncology GroupNETWORK | 8 | Apr 28, 2020 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT00702702 | Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 56 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00735553 | Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 77 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00737282 | Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids | terminated | Phase 3 | 175 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00785356 | Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 8 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00853567 | Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 71 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01069120 | Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 27 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2026source: clinicaltrials